S. Maude

Oncology · 2012–2018

A researcher in the Science corpus: 8 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom S. Maude trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Porter
  2. R. Brentjens
  3. B. Levine
  4. S. Iyer
  5. I. Rivière
  6. J. Kochenderfer
  7. M. Milone

Who trusts S. Maude overall

  1. Jennifer N. Brudno
  2. J. Kochenderfer
  3. Jang-Hwan Cho
  4. D. Teachey
  5. C. June
  6. Yusuf H. Roohani
  7. C. Dunbar
  8. G. Weiner

Papers from S. Maude's perspective

Ordered by how strongly the researchers S. Maude trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia (New England Journal of Medicine)
  2. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (Science Translational Medicine)
  3. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (Science Translational Medicine)
  4. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with… (Blood)
  5. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia (Science Translational Medicine)
  6. Familial and acquired hemophagocytic lymphohistiocytosis (European Journal of Pediatrics)
  7. A Simple Sequentially Rejective Multiple Test Procedure
  8. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis (Pediatric Blood & Cancer)
  9. IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6 (International Journal on Biological Sciences)
  10. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. (Blood)

Their papers